Pfizer denies Nigeria trials were illegal

14 May 2006

Global drug giant Pfizer has denied claims by the Nigerian government that it conducted a meningitis drug trial on children without either government approval or that of the parents and guardians of the patients. The claims were reported in the Washington Post and followed revelations of a report that has remained unpublished for more than five years.

Pfizer "broke international law"

The dispute stems from a 1996 outbreak of meningitis in the Nigerian city of Kano. According to a medical panel reporting to the Nigerian government in 2000, Pfizer had conducted "an illegal trial of an unregistered drug." The committee further accused the drug firm of "exploitation of the ignorant," claiming that parents had not been told that the drug Trovan (trovafloxacin) was experimental and that other treatments were available, notably Switzerland-based drug major Roche's Rocephin (ceftriaxone). The report's conclusions were that Pfizer had violated both Nigerian and international law, notably the Helsinki declaration on medical research ethics and the United Nations' Convention on the Rights of the Child.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight